GoodRx Holdings, Inc. (NASDAQ:GDRX) shares are gaining during Thursday’s premarket session.

The company revealed that it is expanding access to Eli Lilly and Company’s (NYSE:LLY) new oral GLP-1 medication, Foundayo.

GoodRx announced that eligible self-pay consumers can access Foundayo starting at $149 per month.

The company is also expanding access to Zepbound, available to eligible self-pay patients starting at $299 per month at more than 70,000 pharmacies nationwide.

Earnings & Analyst Outlook

GoodRx Holdings is slated to provide its next financial update on May 6, 2026 (estimated).

  • EPS Estimate: 5 cents (Down from 9 cents)
  • Revenue Estimate: $183.88 million (Down from $202.97 million)
  • Valuation: P/E of 23.9x (Indicates fair valuation)

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $5.76. Recent analyst moves include:

  • Wells Fargo: Overweight (Lowers Target to $3.50) (March 4)
  • Citigroup: Buy (Lowers Target to $3.50) (March 3)
  • Goldman Sachs: Neutral (Lowers Target to $2.50) (March 2)

Price Action

GDRX Stock Price Activity: GoodRx Holdings shares were up 4.66% at $2.24 during premarket trading on Thursday, according to Benzinga Pro data.

Photo by JHVEPhoto via Shutterstock